PRÉTOMANID

USDailyMed:Pretomanid J04AK08(WHO) US:℞-onlyEU:Rx-only (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3]oxazine 187235-37-6 456199 DB05154 401693Y 2XOI31YC4N D10722Y ChEMBL227875Y DTXSID8041163 Interactive image C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1NKey:ZLHZLMOSPGACSZ-NSHDSACASA-NN Pretomanidis anantibioticmedication used for the treatment ofmulti-drug-resistant tuberculosisaffecting thelungs.It is generally used together withbedaquilineandlinezolid.It is takenby mouth. The most common side effects includenerve damage,acne, vomiting, headache,low blood sugar, diarrhea, andliver inflammation.It is in thenitroimidazoleclass of medications. Pretomanid was approved for medical use in the United States in August 2019,and in the European Union in July 2020.Pretomanid was developed byTB Alliance.The USFood and Drug Administration(FDA) considers it to be afirst-in-class medication.It is on theWorld Health Organization's List of Essential Medicines.